TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06875128: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatmen

Sponsor: Delcath Systems Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06875128 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06875128 Rescue Dossier →